Record date for the distribution of warrants of series TO4 to current shareholders is set to November 19, 2020
On November 10 2020, the board of directors of Cyxone AB (publ), (“Cyxone” or the “Company”) decided to carry out a Directed Issue (the “Directed Issue”), and to issue warrants of series TO4 to the current shareholders of Cyxone who on the record date holds shares in the Company. The warrants will, to some extent, compensate the current shareholders in the Company for the dilution in the Directed Issue.
The record date to receive warrants of series TO4 has been set to November 19, 2020. Therefore, the last day of trading in the Company’s share including the right to receive warrants of series TO4 is November 17, 2020, and the first day of trading in the Company’s share excluding the right to receive warrants of series TO4 is November 18, 2020.
The current shareholders of Cyxone will receive one (1) warrant of series TO4 for every twenty-eight (28) shares held on the record date. A total of 1,928,157 warrants of series TO4 will be issued to the current shareholders of Cyxone.
The investors that have participated in the Directed Issue will not receive their shares before the record date and will therefore not have the right to receive warrants that are issued to the current shareholders.
The full terms for the warrants of series TO4 will be available at the Company’s website: www.cyxone.com.Terms and information regarding warrants of series TO4
Each warrant of series TO4 will give the holder the right to subscribe for one (1) new share in Cyxone at a subscription price corresponding to 70 percent of the average volume-weighted share price on Nasdaq First North Growth Market during the period from April 29, 2021 to May 12, 2021 (the “Measurement period”). However, the subscription price shall not exceed SEK 7.05 per new share, and not be less than SEK 2.00 per share.
The exercise period for the subscription of new shares with warrants of series TO4 will be from May 17, 2021 up until May 28, 2021.
If all the warrants are exercised for the subscription of new shares, and under the condition that the share price during the Measurement period is SEK 10 or more, Cyxone can receive, at most, an additional SEK 42 million.
Upon full exercise of all the warrants of series TO4, the dilution will amount to approximately 9.37 percent, in proportion to the number of shares after the registration of the Directed Issue.
Cyxone will apply for admission for trading of the warrants issued in the Directed Issue on Nasdaq First North Growth Market as soon as it is possible after the registration of the Directed Issue and the allotment to the current shareholders has been completed.Advisers
Mangold Fondkommission AB acted as the sole bookrunner and financial adviser, and Fredersen Advokatbyrå AB acted as the legal adviser in connection with the Directed Issue.Disclaimer
This is a translation of the original Swedish version of the press release. In case of any discrepancy between this translation and the Swedish original, the latter shall prevail.Contact
Tara Heitner, CEO
Tel: +46 (0)70 781 88 08
211 22 Malmö, Sweden
Mangold Fondkommission AB
Telephone: +46 (0)8 503 015 50
Cyxone AB (publ) (Nasdaq First North Growth Market: CYXO) develops disease modifying therapies for diseases such as rheumatoid arthritis and multiple sclerosis as well as treatments for virally induced acute respiratory disorders. Rabeximod is a Phase 2 candidate drug being evaluated for the management of rheumatoid arthritis and moderate Covid-19 infections. T20K is a Phase 1 candidate drug for treatment of multiple sclerosis. Certified Adviser is Mangold Fondkommission AB, +46 (0)8 503 015 50, firstname.lastname@example.org. For more information, please visit www.cyxone.com.Open Press release